LAG-3 and PD-1 Inhibitors for Esophageal and Gastroesophageal Junction Cancer: A Phase Ib Trial
By Ronan Kelly, MD - Last Updated: March 19, 2025Ronan Kelly, MD, describes his phase Ib trial on the use of nivolumab in combination with the LAG-3 inhibitor relatlimab for the treatment of resectable esophageal/gastroesophageal junction cancer.
Advertisement
He discusses the significance of ctDNA clearance in predicting RFS and OS, as well as the real-world implications of the efficacy of PD-1 and LAG-3 blockades.
Dr. Kelly serves as Director of Oncology at the Charles A. Sammons Cancer Center of Baylor University Medical Center.
Advertisement
Related Posts
Adjuvant nivolumab provides durable long-term DFS benefit and shows an OS advantage in patients with resected EC/GEJC.
Long-term follow-up from KEYNOTE-016 explores pembrolizumab treatment in dMMR/MSI-H solid tumors in advanced CRC.
The addition of concurrent chemoradiation to chemotherapy can improve OS and resection rates in patients with LAGBC.
The Claudin18.2 antibody-drug conjugate IBI343 is well tolerated and shows encouraging efficacy in patients with PDAC.
LEAP-002 long-term follow-up suggests there may be benefit associated with len/pembro for patients with aHCC.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.